Jim Woody

Jim Woody has more than 25 years of pharmaceutical research and management expertise.

He currently serves as Chairman of Oncomed Pharmaceuticals, where he was previously a founder and CEO; he is also a General Partner at Latterell Venture Partners, a venture capital group focusing on early-stage healthcare companies.

He has served in a variety of health and management roles including as President of Roche Bioscience, and CSO and Senior Vice President of R&D for Centocor.

At Centocor, Jim was part of the team that discovered Remicade, used to treat arthritis and which is now one of the best-selling drugs in the world.

He served as Commanding Officer and Director at the US Naval Medical Research and Development Command in Bethesda, Maryland.

In this role he was responsible for the surveillance, detection and therapy for all biologic warfare agents and infectious diseases in the First Gulf War; he was awarded the US Navy Legion of Merit for his service.

He holds an MD from Loma Linda University, and trained in pediatric immunology at Duke University and Boston Children’s Hospital (Harvard).

He further holds a PhD in Immunology from the University of London, and has co-authored more than 140 publications.